UTHR
United TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
The bull read after the May 6, 2026 print is that the quarter was messy but not thesis-breaking: Tyvaso DPI still grew 9%, Orenitram grew 12%, the company kept emphasizing near-term sequential growth recovery, and the pipeline still carries two major planned filings by end of summer 2026 [#8-K-2026-05-06] [#10-Q-2026-05-06]. Secondary coverage suggests at least one analyst was willing to look through the quarter toward IPF and ralinepag optionality, but the packet does not provide enough broad revision detail to treat that as a high-conviction sentiment shift.
Posture
Constructive
Lead driver
Momentum
What changed
3 setup hits (3d) with net bullish as of 2026-06-01.
What can break
Competitive pressure in inhaled prostacyclins remains live; management explicitly described the landscape as dynamic, and secondary analyst coverage flagged Yutrepia share-gain concerns after the print [#8-K-2026-05-06].
Momentum
62
Value
65
Sentiment
55
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $590.00 · Bull $700.00 · Bear $470.00
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $585.18
Why
Momentum62 · Δ7d -5.9
Value65 · Δ7d +0.6
Sentiment55 · Δ7d +8.0
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
62
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.9
Δ21d
-10.3
Value
65
32% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
+1.0
Sentiment
55
33% active weight
Current posture
7d trendImproving
Δ7d
+8.0
Δ21d
+14.9
Why this grade
Composite grade B. Momentum 61.5 / Value 65.3 / Sentiment 54.9
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$23.64B
Beta
0.86
Shares Out
43.06M
P/E (TTM)
18.5
P/S (TTM)
6.74
P/FCF (TTM)
18.89
Rev YoY
+6.8%
EPS YoY
+12.1%
Gross Margin
+88.6%
Op Margin
+47.7%
Net Debt
-$2.97B
Current Ratio
6.40
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology